Abstract
The diagnosis of acromegaly, in an appropriate clinical context, usually relies on lack of GH suppression below 1 μg/l during OGTT coupled with elevated IGF-I levels. On the other hand, in normal subjects glucose-induced inhibition of GH secretory bursts without any further decrease of interpulse GH levels had already been shown. Based on the foregoing, we aimed to compare the diagnostic reliability of OGTT-induced GH nadir with that recorded during 3-h spontaneous GH secretion. In 59 acromegalic patients (17 male and 42 female, age, mean±SE 51.5±1.9, range 21–76 yr) and in 82 normal subjects (43 male and 39 female, age, mean±SE 35.7±1.5, range 15–72 yr) GH secretion was evaluated every 30 min from 0 to 180 min during slow saline infusion or OGTT (75 g at 0 min). A nadir GH concentration below 1 μg/l was recorded in all normal subjects either during OGTT or saline infusion if GH secretion was evaluated over 180 min. In contrast in acromegalic patients a nadir GH concentration below 1 μg/l never occurred in both conditions. This study shows that a 3-h spontaneous GH profile is as reliable as OGTT in the diagnosis of active acromegaly.
Similar content being viewed by others
References
Daughaday W.H., Starkey R.H., Saltman S., Gavin G.R. III, Mills-Dunlap B., Health-Monning E. Characterization of serum growth-hormone (GH) and insulin-like growth factor I in active acromegaly with minimal elevation of serum GH. J. Clin. Endocrinol. Metab. 1987, 65: 617–623.
Hoffenberg R., Howell A., Epstein S. et al. Increasing growth with raise circulating somatomedin but normal immunoassayable growth hormone. Clin. Endocrinol. 1977, 6: 443–448.
Mims R.B., Bethune J.E. Acromegaly with normal fasting growth hormone concentrations but abnormal growth hormone regulation. Ann. Intern. Med. 1974, 81: 781–784.
Melmed S., Ho K., Klibanski A., Reichlin S., Thorner M. Recents advances in pathogenesis, diagnosis and management of acromegaly. J. Clin. Endocrinol. Metab. 1995, 80: 3395–3402.
Giustina A., Barkan A., Casanueva F.F. et al. Criteria for cure of acromegaly: a consensus statement. J. Clin. Endocrinol. Metab. 2000, 85: 526–529.
Clemmons D.R., Van Wyck J.J., Ridgway E.D.C., Kliman B., Kjellberg R.N., Underwood L.E. Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N. Engl. J. Med. 1979, 301: 1138–1142.
Barkan A.L., Beitins I.Z., Kelch R.P. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J. Clin. Endocrinol. Metab. 1988, 67: 69–73.
Ho K.K.Y., Weissberger A.J. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin. Endocrinol. 1994, 41: 75–83.
Rieu M., Girard F., Bricare H., Binoux M. The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. J. Clin. Endocrinol Metab. 1982, 55: 147–153.
Stoffel-Wagner B., Springer W., Bidlingmaier F., Klingmuller D. A comparison of different methods for diagnosing acromegaly. Clin. Endocrinol. 1997, 46: 531–537.
Jasper H., Pennisi P., Vitale M., Mella A., Ropelato G., Chervin A. Evaluation of disease activity by IGF-I and IGF binding protein-3 (IGFBP3) in acromegaly patients distribuited according to a clinical score. J. Endocrinol. Invest. 1999, 22: 29–34.
Smith W.J., Underwood L.E., Clemmons D.R. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J. Clin. Endocrinol. Metab. 1995, 80: 443–449.
Thissen J.P., Ketelslegers J.M., Underwood L.E. Nutritional regulation of the insulin-like growth factors. Endocrine. Rev. 1994, 15: 80–101.
Hall K., Hilding A., Thoren M. Determinants of circulating insulin-like growth factor-I. J. Endocrinol. Invest. 1999, 22: 48–57
Corpas E., Harman S.M., Blackman M.R. Human growth hormone and human aging. Endocrine Rev. 1993, 14: 20–39.
Ghigo E., Aimaretti G., Gianotti L., Bellone J., Arvat E., Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur. J. Endocrinol. 1996, 134: 352–356.
Duncan E., Wass J.A.H. Investigation protocol: acromegaly and its investigation. Clin. Endocrinol. 1999, 50: 285–293.
Earll J.M., Sparks L.L., Forsham PH. Glucose suppression of serum growth hormone in the diagnosis of acromegaly. J. Am. Med. Ass. 1967, 201: 134–136.
Chapman I.M., Hartman M.L., Straume M., Johnson M.L., Veldhuis J.D., Thorner M.O. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than in women. J. Clin. Endocrinol. Metab. 1994, 78: 1312–1319.
Colao A., Lombardi G. Growth-hormone and prolactin excess. Lancet 1998; 352: 1455–1461.
Grecu E.O., Walter R.M., Gold E.M. Paradoxical release of growth hormone during oral glucose tolerance test in patients with abnormal glucose tolerance. Metabolism 1983, 32: 134–137.
Becker M.D., Cook G.C., Wright A.D. Paradoxical elevation of growth hormone in active chronic hepatitis. Lancet 1969, 2: 1035–1039.
Tamai H., Kiyohara K., Mukuta Y. et al. Responses of growth hormone and cortisol to intravenous glucose loading test in patients with anorexia nervosa. Metabolism 1991, 40: 31–34.
Maccario M., Procopio M., Grottoli S. et al. In obesity the somatotrope response to either GHRH or arginine is inhibited by somatostatin or pirenzepine but not by glucose. J. Clin. Endocrinol. Metab. 1995, 80: 3774–3778.
Grottoli S., Maccario M., Procopio M. et al. The somatotrope responsiveness to hexarelin, synthetic hexapeptidde, is refractory to the inhibitory effect of glucose in obesity. Eur. J. Endocrinol. 1995, 135: 678–682.
Semer M., Faria A.C.S., Nery M. et al. Growth hormone pulsatility in active and cured acromegalic subjects. J. Clin. Endocrinol. Metab. 1995, 80: 3767–3770.
Iranmanesh A., Grisso B., Veldhuis J.D. Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatropic men studied with a new ultrasensitive chemiluminescence assay. J. Clin. Endocrinol. Metab. 1994, 78: 526–535.
Melmed S., Jackson I., Klienberg D., Klibanski A. Current treatment guidelines for acromegaly. J. Clin. Endocrinol. Metab. 1998, 83: 2646–2652.
Hattori N., Shimatsu A., Kato Y. et al. Growth hormone responses to oral glucose loading measured by highly sensitive enzyme immunoassay in normal subjects and patients with glucose intolerance and acromegaly. J. Clin. Endocrinol. Metab. 1990, 70: 771–776.
Wass J.A.H. Growth hormone, insulin-like growth factor-I and its binding proteins in follow-up of acromegaly. J. Endocrinol. 1997, 155: S17–S19.
Freda P.U., Kalmon D.P., Jefrey S.P., Sharon L.W. Evaluation of the disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J. Clin. Endocrinol. Metab. 1998, 83: 3808–3816.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grottoli, S., Razzore, P., Gaia, D. et al. Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. J Endocrinol Invest 26, 123–127 (2003). https://doi.org/10.1007/BF03345139
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345139